The phase 3 trial results of Eli Lilly and Co.’s solanezumab and Janssen/Pfizer’s bapineuzumab appeared in the January 23rd edition of the New England Journal of Medicine.
In an accompanying editorial in NEJM, JPND Scientific Advisory Board members Eric Karran of Alzheimers Research U.K., and John Hardy of University College London (neither of whom were involved in the trials), gave their insights into the results.
Both monoclonal antibodies failed to slow cognitive or functional decline in patients with mild to moderate Alzheimers disease. However, each drug hinted at smaller benefits and bolstered the idea that amyloid-related treatments, if they are to work, must be applied early in the disease process, perhaps before cognitive symptoms emerge.
Source: AlzForum